At 16x guided 2026 adjusted operating profit and 34x the guided cash floor, with clean margin lower than a year ago and the 2027 step resting on suppliers, Embraer's equity is fully valued — a franchise worth owning at a price the market is no longer offering.
Read Article ›SharkNinja's operating problem this year was making enough product, and the market's residual habit of grouping it with builders and big-ticket retailers understates what the holiday quarter can deliver.
Read Article ›The unusual thing about IMAX today is that the bull case and the bear case are both right and they run on different clocks.
Read Article ›At 16 times forward earnings, this price embeds no margin expansion, no buyback, and a backlog that converts on the market's timetable rather than the contract's.
Read Article ›What kills single-asset biotechs is not usually the science; it is being forced to sell equity into bad news and AbCellera has removed that mechanism for the window in question.
Read Article ›Matador's reported earnings and its cash earnings have been separated by a contract with a termination date, and the market has been pricing the former.
Read Article ›The market is now valuing AppLovin below a diversified mega-cap advertising platform on forward earnings while it grows two to three times as fast, generates over 60% net margins, carries essentially no net debt, and retires stock.
Read Article ›At eleven times forward earnings against a mid-thirties return on equity and a client cohort deepening at 34% per relationship, the risk-reward is skewed to the upside, and the stock is worth owning even after the run.
Read Article ›The market has assigned MercadoLibre the multiple of a business whose profitability has been permanently reset, while the disclosures show a company deliberately buying engagement, logistics density and a 20%-plus-margin loan book with money it could stop spending in a quarter...
Read Article ›At 14 times forward earnings for a franchise compounding earnings at roughly a fifth a year on a 33% return on equity, with a funding book half-deployed and a Mexican bank that only became a bank last month, the market is underwriting the credit fear and paying nothing for the...
Read Article ›At roughly 25x next year's consensus earnings for a business converting three-quarters of net income to cash and taking share on both sides of the Atlantic, Eli Lilly is mispriced to the upside — and the risk-reward has not turned, it has merely become less generous than it wa...
Read Article ›The market's error here is not the 50% de-rating — three guide-downs earned it — but the assumption that the cutting continues.
Read Article ›At 15.5 times forward earnings and a 6.6% cash yield on enterprise value, the market is not pricing a debate, it is pricing an answer – and the answer it has chosen is contradicted by every disclosure FactSet has made since the shares halved.
Read Article ›The bull case needs nothing new — only that a brand posting 17% growth in its own channels, with inventory down 5% and a raised earnings guide, is not the brand that gets caught in someone else's clearance event.
Read Article ›What tips the balance is that the approval was not the whole catalyst — it was the start of a data stream that gets richer, not thinner, from here.
Read Article ›The company is a fixed-fee volume engine that beat on reliability, is forward-sold through year-end, has a funded ramp to 60–63 MTPA nearly complete, and is retiring roughly 3% of its shares a year.
Read Article ›Guidance went up, not down; the contract book lengthened; a landmark acquisition closed and its integration proceeded on plan.
Read Article ›The reason the multiple is compressed is not that anyone doubts the ad engine; it is that Meta, alone among the hyperscalers, has no third-party cloud line absorbing the spend.
Read Article ›The harder, less-discussed truth about BridgeBio is that the equity sitting on top of this franchise is a thin residual behind a capital structure that private-credit and private-equity sponsors engineered to harvest the ramp first.
Read Article ›The market broke this stock on a narrative about 2028 and has not fully repaired it against an operating record that keeps improving.
Read Article ›